By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said it started two new U.S. collaborations to position its digital tomosynthesis system Nanox.ARC across the country. The first partnership is with Howard Technology Solutions to utilize 300 Nanox.ARC over a period...

By Karen Roman SkylineDx said it can predict metastases and outperform existing staging systems for the country’s second most common type of skin cancer, Cutaneous Squamous Cell Carcinoma (CSCC). The results will be presented at the 22nd European Association of...

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said Axel-Sven Malkomes joined the company as Chief Financial Officer, while Susan Coles and Pamela Herbster started their roles as Chief Legal Officer and Chief People Officer, respectively. The additions come as Inventiva...

By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said a peer-reviewed study published in the Institute of Electrical and Electronics Engineers Sensors Journal supported the feasibility of long-life implantable continuous glucose monitors like the devices the company develops. The article came...

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) announced it signed two new partnerships to continue deploying its digital tomosynthesis system Nanox.ARC both nationally and globally. The first collaboration is with Digital X-Ray Imaging Inc. to market, install and support...

By Daniella Parra Callio Therapeutics presented preclinical data at AACR that supports the first dual-payload antibody drug conjugate in Phase 1 for HER2-expressing cancers. While approved ADC drugs like Enhertu work initially, treatment resistance builds over time because of its...

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said it started two new collaborations to deploy its digital tomosynthesis system Nanox.ARC across the U.S. The first partnership aims to use 12 Nanox.ARC with Integrity Medical Service in Colorado, Wyoming and...

By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said it will request an Investigational Device Exemption (IDE) from the FDA for its continuous blood glucose monitoring technology. This submission follows the completion of clinical trials in Brazil and Australia, and is...

By Karen Roman SkylineDx said its Merlin CP-GEP molecular test identifies a subset of T1a melanoma patients with sentinel lymph node (SLN) positivity above guideline thresholds. The National Comprehensive Cancer Network updated its guidelines recognizing the Merlin CP-GEP as the...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it presented new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders taking place March 17-21, 2026, in Copenhagen and online. The data displays efforts...